Skip to main content
SpringerLink
Log in
Book cover

BRAF Targets in Melanoma

Biological Mechanisms, Resistance, and Drug Discovery

  • Book
  • © 2015

Overview

Editors:
  1. Ryan J. Sullivan

    1. Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Examines BRAF-directed targets in melanoma including molecular biology/signal transduction, molecular diagnostics, immunology, and next-generation analytics
  • Highlights and summarizes the unique biological mechanisms of how BRAF-inhibitors work and why they ultimately fail
  • Explores combinations of molecular targeted therapy and how molecular targeted therapy may interact with immune-based therapy
  • Includes supplementary material: sn.pub/extras

Part of the book series: Cancer Drug Discovery and Development (CDD&D, volume 82)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (9 chapters)

  1. Front Matter

    Pages i-viii
    Download chapter PDF

  2. Melanoma: Historical Context

    • Suraj Venna, Sekwon Jang, Michael B. Atkins
    Pages 1-23

  3. Melanoma Pathogenesis

    • Jennifer A. Lo, David E. Fisher
    Pages 25-45

  4. Molecular Diagnostics and Tumor Mutational Analysis

    • Melissa A. Wilson, Katherine L. Nathanson
    Pages 47-65

  5. Clinical Utility of BRAF-Targeted Therapy in Melanoma

    • Jeffrey A. Sosman, Douglas B. Johnson
    Pages 67-84

  6. The Ethics of Randomized Trials in Oncology

    • Pallavi Kumar, Ryan J. Sullivan
    Pages 85-103

  7. Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma

    • Michael A. Davies
    Pages 105-135

  8. Targeting the Cell Cycle and p53 in Combination with BRAF-Directed Therapy

    • Dale Han, Keiran SM Smalley
    Pages 137-162

  9. Combination BRAF-Directed Therapy and Immunotherapy

    • Zachary A. Cooper, Zain Ahmed, Jennifer A. Wargo
    Pages 163-182

  10. Moving Forward: Making BRAF-Targeted Therapy Better

    • Keith T. Flaherty
    Pages 183-201

  11. Back Matter

    Pages 203-204
    Download chapter PDF
Back to top

Keywords

About this book

​This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that this drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.

Editors and Affiliations

  • Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, USA

    Ryan J. Sullivan

About the editor

Dr. Ryan J. Sullivan is affiliated with Massachusetts General Hospital and Dana Farber. His research interests are in the development of novel molecular therapeutic agents for Kaposi sarcoma (KS) and malignant melanoma and the translation of promising preclinical findings into early stage clinical trials. He serves as the co-director of the Eugene Michael Egan Melanoma Translational Research Laboratory at Beth Israel Deaconess Medical Center (BIDMC) and is actively investigating promising biomarkers of response and benefit to immunotherapy and molecular targeted therapy for patients with melanoma.

Bibliographic Information

  • Book Title: BRAF Targets in Melanoma

  • Book Subtitle: Biological Mechanisms, Resistance, and Drug Discovery

  • Editors: Ryan J. Sullivan

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1007/978-1-4939-2143-0

  • Publisher: Humana New York, NY

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer Science+Business Media New York 2015

  • Hardcover ISBN: 978-1-4939-2142-3Published: 25 November 2014

  • Softcover ISBN: 978-1-4939-5348-6Published: 10 September 2016

  • eBook ISBN: 978-1-4939-2143-0Published: 24 November 2014

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: VIII, 204

  • Number of Illustrations: 5 b/w illustrations, 21 illustrations in colour

  • Topics: Cancer Research, Molecular Medicine, Medical Microbiology, Pharmacology/Toxicology

Publish with us

Policies and ethics

Back to top

Search

Navigation